CONTEMPORARY SCREENING FOR THE DETECTION OF LUNG CANCER

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项随机试验的主要目的是确定在高危队列中，使用低剂量螺旋CT进行肺癌筛查相对于胸片筛查是否能降低肺癌特异性死亡率。 第二个目标是从有和没有病理证实的肺癌的高风险个体中开发组织库。在BIDMC的试验中将入组1000例受试者，为期3年;一半受试者将随机接受低剂量螺旋CT（实验组），另一半受试者将随机接受胸部X线摄影（对照组）。 本研究成像部分的主要终点是肺癌特异性死亡率。在研究的生物标记部分，假设可以在血液、痰液或尿液中鉴定生物分子标记，这可以增强对癌症之前和与癌症相关的遗传事件的理解。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aim of this randomized trial is to determine whether lung cancer screening using low-dose helical CT reduces lung cancer-specific mortality relative to screening with chest radiographs in a high risk cohort. A secondary aim is to develop a tissue bank from individuals at high risk of lung cancer both with and without pathologically proven lung cancers. 1000 subjects will be enrolled in the trial at BIDMC over a 3 year period; half will be randomized to low dose spiral CT (experimental arm) and half will be randomized to chest radiography (control arm). The primary endpoint of the imaging part of the study is lung cancer specific mortality. In the bio-marker portion of the study, the hypothesis is that biomolecular markers may be identified in blood, sputum or urine which can enhance understanding of genetic events preceding and associated with cancer.